KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.75

Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling.

Sina A Beer, David A Cairns, Charlotte Pawlyn, Amy Holroyd, Elsa Ferris, Gordon Cook, Mark Drayson, Kevin Boyd, Paula Proszek, Faith E Davies, Ruth de Tute, Matthew Jenner, Gareth J Morgan, Roger Owen, Michael Hubank, Richard Houlston, Graham Jackson, Martin F Kaiser

Blood 146(22) 2670-2680

PMID40834881
PMCIDPMC12824701
DOI10.1182/blood.2025029987
发表日期2025-08-20
入排依据:This is a secondary, biomarker-focused analysis from the Myeloma-XI trial, examining the prognostic value of risk stratification. While the underlying trial is a Phase III randomized trial with drug interventions and time-to-event endpoints, this specific report does not present the primary or key secondary efficacy results of a drug-containing intervention vs. control. It is a subgroup/biomarker analysis.
摘要

摘要

Functional high-risk (FHR) multiple myeloma (MM) is defined as an unexpected, early relapse (ER) of disease in the absence of baseline molecular or clinical risk factors (RF), making FHR MM inherently dependent on which RFs were assessed at diagnosis, and what treatment patients received. To establish the true incidence of FHR, we analyzed uniformly treated, transplant-eligible patients from the Myeloma-XI (MyXI) trial that had been profiled for the International Myeloma Society and Working Group (IMS/IMWG) defined high-risk cytogenetic aberrations (HRCA), and the SKY92 gene expression HR signature (GEP-HR). A total of 135 MyXI patients were studied, with a median follow-up of 88 months; 25 (18.5%) experienced ER, defined as relapse <18 months from maintenance randomization post-autologous stem-cell transplantation. Hereof, 15 (60%) were IMS/IMWG-HR at diagnosis, of whom 8 were also GEP-HR. Another 6 patients were GEP-HR only and would have been missed by IMS/IMWG-HR. Among 4 patients with IMS/IMWG- and GEP-standard risk, 2 had isolated HR markers at diagnosis, leaving only 2 patients (8% of ER; 1.5% of all) truly meeting all FHR-criteria. Combined IMS/IMWG-HR and GEP-HR profiling identified 84% of ER, and differentiated long-term outcome across all 135 patients: co-occurring IMS/IMWG and GEP-HR was associated with very short overall survival compared to the absence of both (HR = 13.1; 95% CI, 6.5-26.1, P < .0001), followed by GEP-HR only (HR = 5.1; 95% CI, 2.4-11.1, P < .0001) and IMS/IMWG-HR only (HR = 3.2; 95% CI, 1.6-6.2, P = .0007). Our results support more comprehensive baseline diagnostic profiling to identify those at risk of ER upfront. The trials were registered at the ISRCTN Registry as ISRCTN49407852 and at clinicaltrials.gov as #NCT01554852.

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

Figure 2

Figure 2. Kaplan-Meier survival estimates for the entire study cohort (n = 135). (A) PFS and (B) OS stratified by IMS/IMWG-HR and GEP-HR classification (SR, IMS/IMWG-HR, GEP-HR, IMS/IMWG-HR & GEP-HR). x-axis, time since maintenance randomization (months); y-axis, survival probability; risk tables, number of patients at risk. Log-rank P values are shown. Figure created with biorender.com . Houlston R. (2025) https://biorender.com/0vv82j9 .

A

Progression free survival

Figure 2 · Panel A

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme upward reversal
查看结果
B

Overall survival

Figure 2 · Panel B

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 4:extreme upward reversal
查看结果
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

captionless-figureGraphical abstract
非 KM Figure
Figure 1Figure 1. Study overview and risk profiles of ER patients. (A) Functional HR MM in 135 MyXI trial patients was determined using advanced molecular profiling, including HRCA per updated IMS/IMWG-HR criteria and GEP-HR based on the SKY92 signature. (B) Bar chart illustrating the composition of 4 risk groups based on IMS/IMWG-HR and GEP-HR classification (SR, IMS/IMWG-HR, GEP-HR, and IMS/IMWG-HR & GEP-HR) in the 25 patients with ER. CTPC, circulating tumor plasma cells; Lena, lenalidomide; PCL, plasma cell leukemia. Figure created with biorender.com . Houlston R. (2025) https://biorender.com/0vv82j9 .
非 KM Figure
Figure 3Figure 3. Composition of HR features according to updated IMS/IMWG-HR classification. (A) Sankey plot illustrating the composition and contribution of individual risk factors to the updated IMS/IMWG-HR classification. Six groups are displayed based on combinatorial risk features, including HRCA count, GEP signature, and isolated b2m elevation. Elevated b2m is subdivided by creatinine levels below or above the ULN, according to the IMS/IMWG-HR definition. One patient with GEP-HR carried an isolated del(17p) and was therefore also classified as IMS/IMWG-HR. TP53 mutation status was not included in this analysis because only 11 patients in the study had available information. (B) Co-occurrence of HR genetic features in patients harboring del(1p32). Each row represents 1 of 19 individual patients, while columns indicate the presence (gray) or absence (white) of an HR feature, including IMS/IMWG-defined HRCAs and GEP-HR. Biallelic del(1p32) are highlighted in dark red. ULN, upper limit of normal. Figure created with biorender.com . Houlston R. (2025) https://biorender.com/0vv82j9 .
非 KM Figure
Figure 4Figure 4. Oncoplot illustrating HR features at an individual patient level (n = 135), including IMS/IMWG-defined HRCAs, GEP-HR, t(11;14), and elevated b2m or LDH. ER as in PFS (defined as <18 months or <24 months) and OS events (at 48 and 60 months) are shown in red, while no event displayed in gray. Co-occurrence of ≥2 HR features appear in dark blue, single HR features in light purple, and no HR feature in white. Translocation t(11;14) is separately listed in green. Elevated laboratory parameters (b2m, LDH) are marked in dark purple. TP53 mutation status was not included in this analysis, as only 11 patients in the study had available information. LDH, lactate dehydrogenase. Figure created with biorender.com . Houlston R. (2025) https://biorender.com/0vv82j9 .
非 KM Figure